COVID-19 Update: See the latest on our visitor policy here. Learn More
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients with Hepatic Dominant Ocular Melanoma
- To provide access to Melphalan/HDS to patients with hepatic-dominant metastatic ocular melanoma. - To evaluate the safety of treatment with Melphalan/HDS in patients with hepatic-dominant metastatic ocular melanoma. Objective Response Rate (ORR) (complete response + partial response) as determined by the Investigator.
Chemotherapy (NOS); Therapy (NOS)
Alkeran (Melphalan); Melphalan (); Not Applicable ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.